^
    Back
    Association details:
    Biomarker:EGFR A763_Y764insFQEA
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    IASLC-WCLC 2021
    Title:

    FP12.05 - The Intrinsic Limitation and Clinical Impact of Mutant Allele-Specific Real-Time PCR-Based EGFR Mutation Assay in NSCLC

    Published date:
    08/18/2021
    Excerpt:
    Two patients showed EGFR A763_Y764insFQEA, which has been considered as sensitive to classical EGFR tyrosine kinase inhibitors (EGFR-TKIs). Two patients (EGFR A763_Y764insFQEA and EGFR T751_I759>S) had received erlotinib during their treatment course and both of them showed stable disease with a progression-free survival of 5.9 and 10.1 months, respectively.
    Test:
    FoundationOne® CDx, cobas® EGFR Mutation Test v2
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Sci Transl Med
    Title:

    Structural, biochemical and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

    Excerpt:
    Response to EGFR TKIs of NSCLCs harboring EGFR exon 20 insertion mutations.
    DOI:
    10.1126/scitranslmed.3007205
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Mol Cancer Ther
    Title:

    EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter

    Excerpt:
    EGFR exon 20 insertion A763_Y764insFQEA was detected on sequencing of the primary tumor...His disease response despite the lower erlotinib dose shows that this particular mutation is likely a sensitizing mutation to EGFR TKI, despite its location in exon 20...
    DOI:
    10.1158/1535-7163.MCT-13-0192